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Background: Central pontine myelinolysis (CPM) is a demyelinating disorder of the central basis pontis that is often
associated with osmotic stress. The aquaporin water channels (AQPs) have been pathogenically implicated because
serum osmolarity changes redistribute water and osmolytes among various central nervous system compartments.
Results: We characterized the immunoreactivity of aquaporin-1 and aquaporin-4 (AQP1 and AQP4) and associated
neuropathology in microscopic transverse sections from archival autopsied pontine tissue from 6 patients with
pathologically confirmed CPM. Loss of both AQP1 and AQP4 was evident within demyelinating lesions in four of
the six cases, despite the presence of glial fibrillary acidic protein (GFAP)-positive astrocytes. Lesional astrocytes
were small, and exhibited fewer and shorter processes than perilesional astrocytes. In two of the six cases,
astrocytes within demyelinating lesions exhibited increased AQP1 and AQP4 immunoreactivities, and gemistocytes
and mitotic astrocytes were numerous. Blinded review of medical records revealed that all four cases lacking
lesional AQP1 and AQP4 immunoreactivities were male, whereas the two cases with enhanced lesional AQP1
and AQP4 immunoreactivities were female.
Conclusions: This report is the first to establish astrocytic AQP loss in a subset of human CPM cases and suggests
AQP1 and AQP4 may be involved in the pathogenesis of CPM. Further studies are required to determine whether
the loss of AQP1 and AQP4 is restricted to male CPM patients, or rather may be a feature associated with specific
underlying precipitants of CPM that may be more common among men. Non-rodent experimental models are
needed to better clarify the complex and dynamic mechanisms involved in the regulation of AQPs in CPM, in order
to determine whether it occurs secondary to the destructive disease process, or represents a compensatory
mechanism protecting the astrocyte against apoptosis.
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Central pontine myelinolysis (CPM) is a demyelinating
disorder affecting the central basis pontis [1,2]. Lesions
characteristically exhibit apoptotic cells, loss of oligo-
dendrocytes, microgliosis, astrogliosis, preservation of
neurons and axons, and infiltration by macrophages
[3-10]. Inflammation usually is lacking, but the presence
of mild lymphocytic inflammatory infiltrates has been
reported and does not exclude the diagnosis [11].* Correspondence: bogdan.popescu@usask.ca; clucchinetti@mayo.edu
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reproduction in any medium, provided the orRapid correction of chronic hyponatremia is a known
cause of CPM, but the molecular pathogenesis remains
elusive [3,4,6,7,12]. CPM occurs in the context of se-
vere illness, and is commonly a complication of condi-
tions with altered serum Na+ levels: alcoholism, liver
transplantation, malnutrition, hepatic cirrhosis, burns
or the syndrome of inappropriate antidiuresis (SIAD)
[11,13-16]. Recognition that CPM also occurs when
other serum osmolytes are altered has prompted the
use of “osmotic demyelination syndrome” as alternative
terminology [17].
Changes in serum osmolarity are recognized to cause
cerebral edema and redistribution of water and inorganic
and organic osmolytes among various central nervous
system (CNS) compartments [18-21]. Astrocytes, whichl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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enwrap synapses and blood vessels and participate in
blood–brain barrier maintenance. They are therefore in
a unique and critical position for controlling brain vol-
ume changes [22,23]. Aquaporins (AQPs) are key regula-
tors of brain volume homeostasis. While aquaporin-4
(AQP4) has been considered the major CNS water chan-
nel and is confined to astrocytes and ependyma [24,25],
recent studies have shown that astrocytes also express
aquaporin-1 (AQP1) in human and non-human primate
brains [26-28]. However the complementary and/or re-
dundant roles of astrocytic AQP1 and AQP4 in regu-
lation of water homeostasis in the human CNS have yet
to be addressed. This study is the first to systematically
characterize astrocyte pathology and expression of AQP1
and AQP4 proteins in human CPM lesions.
Results
General neuropathological characteristics of CPM lesions
All lesions identified in CNS tissues examined from
the 6 CPM patients exhibited active demyelination
(Figure 1a, e, i; Figure 2g, h; Figure 3c). Lesions affected
the base of the central pons symmetrically (Figure 1a, e, i;
Figure 2a; Figure 3a). There was relative preservation
of axons and neurons (Figure 2l, m) and, to some ex-
tent, of myelin (Figure 1e, i; Figure 2c, g, h; Figure 3c).
All lesions were heavily infiltrated by activated macro-
phages (Figure 2a, b; Figure 3a, b) containing abundant
myelin degradation products, a hallmark of active de-
myelination (Figure 2g, h; Figure 3c). There was a mild
degree of T lymphocyte infiltration around vessels and
in the parenchyma (Figure 2n; Figure 3o), and evidence
of axonal swelling (Figure 2l) and oligodendrocyte
apoptosis (Figure 2o). No deposits of complement acti-
vation products were found.
Nonlesional pontine white matter tracts were fre-
quently vacuolated (Figure 4d-i), compatible with intra-
myelinic edema (Figure 4e, inset), and were infiltrated
by microglia (Figure 4i). However, myelin was preserved
(Figure 4b), and AQP4 (Figure 4f ), AQP1 (Figure 4g)
and GFAP (Figure 4h) immunoreactivities were of
normal intensity. In normal appearing gray and white
matter there was evidence of prominent microglial acti-
vation (Figure 4j, k), rare clusters of small macrophages
(Figure 4j), and ballooned and red ischemic neurons
(Figure 4l, m).
Expression of AQP1 and AQP4 in the normal pons
Astrocytes in the normal pons expressed both AQP1
and AQP4 (Figure 5). No differences were observed be-
tween the female and male controls.
Astrocytes in the pontine white matter tracts expressed
preferentially, but not exclusively, AQP1 (Figure 5a-c).
AQP1 in the white matter was highly concentrated on themembrane of the astrocytic cell bodies and in all astrocytic
foot processes, including those abutting blood vessels
(Figure 5d). AQP4 immunoreactivity in the white matter
was mainly observed in astrocytic foot processes abutting
blood vessels (Figure 5f).
Astrocytes in the pontine grey matter nuclei preferen-
tially, but not exclusively, expressed AQP4 (Figure 5a-c).
AQP4 positive astrocytic processes enveloped the blood
vessels as well as the neuronal cell bodies (Figure 5g).
AQP1 immunoreactivity in the pontine nuclei was pref-
erentially observed around blood vessels and around
some, but not all neurons (Figure 5e).
Astrocytic pathology in CPM lesions
Loss of AQP1 and AQP4 was evident within demyelinat-
ing lesions in four of the six cases (Table 1, Figure 1b, f,
c, g; Figure 2d, e). Areas with loss of AQPs (Figure 1b, c,
f, g; Figure 2d, e) corresponded to areas of demyelination
(Figure 1a, e; Figure 2d, e) and macrophage infiltration
(Figure 2a, b), and AQP immunoreactivity was enhanced
at the lesion borders (Figure 4a, b). All four cases dem-
onstrated a loss of the characteristic perivascular distri-
bution of AQP4 (Figure 2i) and AQP1 (Figure 2j) within
the area of active demyelination. Beyond the demyelinat-
ing lesions, AQP1 and AQP4 immunoreactivities were
preserved (Figure 1b, c, f, g). Lesions uniformly retained
GFAP-immunoreactive astrocytes, despite AQP1 and
AQP4 loss (Figure 2f, k), but astrocyte numbers were re-
duced. Lesional astrocytes were smaller and had fewer
and shorter processes (Figure 2k) than perilesional astro-
cytes (Figure 4c), giving the impression of GFAP loss
within lesions when sections were observed under low
magnification (Figure 1d, h). Gemistocytes were rare
within lesions, but were abundant at lesion borders
(Figure 4a-c). The nuclear condensation and fragmentation
typical of apoptosis was not observed in either lesional
or non-lesional astrocytes. Occasional macrophages con-
tained GFAP-positive material (Figure 2k, lower inset), and
Rosenthal fibers were present (Figure 2p).
In two of the six cases astrocytes within demyelinating
lesions exhibited enhanced AQP1 and AQP4 immu-
noreactivity (Table 1; Figure 1j, k; Figure 3d-g, j-l). In
contrast to lesions with loss of AQPs, these lesions
exhibited astroglial activation, numerous gemistocytes,
and abundant mitoses (Figure 3d-l), as well as pronounced
GFAP immunoreactivity (Figure 3m, n). Occasional mac-
rophages contained in their cytoplasm degradation prod-
ucts of AQP4 (Figure 3d), AQP1 (Figure 3j) and GFAP
(Figure 3m).
Demographics and clinical characteristics of the CPM
patients (Table 1)
Blinded review of medical records revealed that all 4
CPM cases with lesional loss of AQP1 and AQP 4
Figure 1 AQP1, AQP4 and GFAP protein expression in human CPM lesions. (a-d) A demyelinated lesion in the central basis pontis (a) of a
56-year-old man with CPM in context of rapidly corrected hyponatremia shows loss of astrocytic AQP4 extending beyond the area of
demyelination (b), loss of AQP1 (c), but retained GFAP (d); (e-h) A CPM lesion in the central basis pontis of a 53-year-old man with CPM and
severe dehydration, malnutrition and hypernatremia shows relative preservation of myelin (e), loss of astrocytic AQP4 (f), AQP1 (g), but preserved
GFAP (h); (i-l) A demyelinated lesion in the central basis pontis (i) of a 24-year-old woman with CPM in the context of hepatic failure and
hypokalemia shows increased AQP4 (j), AQP1 (k) and GFAP expression (l); (a, e, i) PLP; (b,f, j) AQP4; (c, g, k) AQP1; (d, h, l) GFAP;
(scale bar = 5 mm).
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increased lesional AQP1 and AQP4 immunoreactivities
were female. Median age at hospitalization was 49 years
(range 24–68). Median disease duration (interval to
death from arrival at hospital or from clinical onset of
CPM) was 9 days (range 1–60).
All cases had clinical evidence of an osmotic disturb-
ance or had an underlying condition which predisposed
to the development of CPM (Table 1). Patient 1 hadsevere hyponatremia in the setting of alcoholism. In
correcting the hyponatremia, serum Na+ increased by
2 mEq/L in the first 24 hours and by another 12 mEq/L
in the next 24 hours (Figure 1a-d) [3,6,11-16]. Patient 2
had malnutrition, severe dehydration, and hypernatremia
(172 mEq/L) (Figure 1e-h; Figure 2) [11,13-16]. Patient
3 had hyponatremia following liver transplantation
[11,13-16,29-31]. Patient 4 had small-cell lung carcin-
oma with brain and liver metastases, abnormal liver
Figure 2 CPM lesions with loss of AQPs. (a) The demyelinated lesion in the central basis pontis (e-h) is heavily infiltrated with activated
macrophages (KiM1P, scale bar = 5 mm); (b) Higher magnification of an area of macrophage infiltration (KiM1P, scale bar = 500 μm) also shows
(c) relative myelin preservation (PLP, scale bar = 500 μm), (d) loss of AQP4 (AQP4, scale bar = 500 μm), (e) loss of AQP1 (AQP1, scale bar =
500 μm), but (f) preserved GFAP immunoreactivity (GFAP, scale bar = 500 μm); Despite preservation of myelin, the presence of macrophages
containing myelin degradation products both in the (g) gray matter (PLP, scale bar = 50 μm) and (h) white matter (PLP, scale bar = 50 μm) is
consistent with active demyelination; The normal perivascular distribution of (i) AQP4 (AQP4, scale bar = 50 μm) and (j) AQP1 (AQP1, scale bar =
50 μm) is lost, but (k) small GFAP-immunoreactive astrocytes with short processes are still present in lesions; upper inset shows such an astrocyte
in close contact with two macrophages; lower inset shows a macrophage containing GFAP + degradation products (GFAP, scale bar = 50 μm,
upper inset scale bar = 25 μm, lower inset scale bar = 12.5 μm); (l) Axons are preserved, but the presence of axonal swellings (arrows) indicates
axonal injury (NF, scale bar = 50 μm); (m) Neurons are relatively well preserved (HE, scale bar = 50 μm); (n) The lesion also contains mild
parenchymal and perivascular T-cell inflammation (CD3, scale bar = 50 μm); (o) Apoptotic oligodendrocytes (arrowheads) are present (PLP, scale
bar = 50 μm); (p) Rosenthal fibers are also present (HE, scale bar = 100 μm).
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SIAD (presumed to be paraneoplastic) as the precipitat-
ing factor for CPM [11,14]. Patient 5 had hepatic failure
and hypokalemia (Figure 1i-l; Figure 3) [1,11,13-16,32].
Patient 6 had diabetes mellitus type II [11,13-16,33,34].
Discussion
CPM lesions are characterized by astrocytopathy
Apoptosis and loss of oligodendrocytes are traditionally
considered the pathological hallmarks of CPM. However
we found in a subset of CPM cases that astrocytes were
variably reduced in numbers, were small with fewer and
shorter processes, and AQP1 and AQP4 immunoreactiv-
ities were lost within actively demyelinating regions with
relative preservation of myelin. These findings suggest
that prominent degenerative changes in astrocytes may
precede demyelination. Astrocyte damage has been de-
scribed in a single previous report [8], however this is
the first study characterizing in detail the predominant
astrocytic injury in human CPM. Although autopsystudies do not permit definite determination of whether
this astrocytic damage is primary or secondary, a rat
model of osmotic demyelination suggests that rapid cor-
rection of hyponatremia triggers astrocytic damage in
male rats, and that ensuing loss of trophic communica-
tion between astrocytes and oligodendrocytes results in
inflammation, microglial activation, oligodendrocyte in-
jury, and subsequent demyelination [35]. The cons-
tellation of neuropathological findings we observed,
particularly among four of the CPM patients, implies a
similar sequence of pathogenic events, with two notable
differences. First, GFAP immunoreactivity is lost in rat
lesional astrocytes, but is retained in lesional astrocytes
of patients with CPM, despite a loss of both AQP1 and
AQP4. This argues against the loss of AQPs being
strictly due to a loss of astrocytes. Second, in the rat
CPM model, lesional astrocytes show signs of extensive
apoptosis, whereas apoptotic astrocytes were not evident
in human CPM. Interspecies and interregional astrocytic
heterogeneity may explain these discrepancies. Most
Figure 3 CPM lesions with increased expression of AQPs. (a) The demyelinated lesion in the central basis pontis (Figure 2i-l) is heavily
infiltrated with activated macrophages (KiM1P, scale bar = 5 mm); (b) Higher magnification of an area of macrophage infiltration (KiM1P, scale
bar = 100 μm) also shows (c) relative myelin preservation and myelin containing macrophages (arrows) consistent with active demyelination (PLP,
scale bar = 50 μm); (d, e) The lesion shows increased AQP4 expression, occasional macrophages containing AQP4-immunoreactive degradation
products (d, arrow), AQP4-positive gemistocytic astrocytes (e, arrows) (AQP4, scale bar = 50 μm); (f) Mitotic astrocytes are present (HE, scale
bar = 25 μm) and (g) AQP4 immunoreactive (AQP4, scale bar = 25 μm); (h) Gemistocytes are also present (HE, scale bar = 25 μm), and (i) AQP4
immunoreactive (AQP4, scale bar = 25 μm); (j, k, l) The lesion shows increased AQP1 expression, occasional macrophages containing AQP1-
immunoreactive degradation products (j, arrow head), AQP1-positive gemistocytic astrocytes (j, k, l, arrows) and AQP1-positive mitotic astrocytes
(j, inset arrow) (AQP1, scale bar = 50 μm); (m, n) The lesion shows increased GFAP immunoreactivity, tissue vacuolation, occasional macrophages
containing GFAP + degradation products (m, inset), GFAP + gemistocytic astrocytes (m, n, arrows) as well as GFAP +mitotic astrocytes (n, arrow
head) (GFAP, scale bar = 50 μm, inset scale bar = 25 μm); (o) Parenchymal inflammation is also present (CD3, scale bar = 25 μm).
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CPM lesions typically reside in the external capsule,
claustrum, corpus striatum, neocortex, hippocampus
and anterior commissure [3,4]. Furthermore, unlike ro-
dent astrocytes which only express AQP4, astrocytes in
the human brain express both AQP1 and AQP4 [27,28].
Species and CNS differences with respect to astrocyte
morphology, properties and functions therefore exist
and have been described previously in both the normal
and diseased brain [36-38].
Relevance of AQPs to CPM
A unique finding in our study is that immunoreactivity
for AQP proteins is lost in some actively demyelinatinglesions in human CPM. This finding was not universal.
Two of the six cases had an increase of AQP1 and
AQP4 immunoreactivities within actively demyelinating
CPM lesions. Complex dynamic processes that maintain
water homeostasis likely contribute to the discordance
of these findings. As the principal water channels in hu-
man CNS astrocytes, both AQP1 and AQP4 are involved
indirectly in osmolyte movement through functional and
molecular interactions with numerous ion channels and
osmolyte transporters [18-21].
The observed loss of AQP1 and AQP4 in four of six
cases may reflect a compensatory astrocytic response to a
hypotonic milieu. The astrocyte response anticipated in a
hypotonic environment is swelling due to osmotically-
Figure 4 Neuropathology of perilesional areas. Gemistocytes (arrows in a-c) are present and the expression of (a) AQP4 (AQP4, scale bar =
50 μm), (b) AQP1 (AQP1, scale bar = 50 μm), and (c) GFAP (GFAP, scale bar = 50 μm) is increased at the lesions’ borders. (d) Vacuolated white
matter (HE, scale bar = 250 μm) with the appearance of (e) intramyelinic edema (inset shows higher magnification) is a common feature of
nonlesional pontine white matter tracts with preserved myelin (PLP, scale bar = 250 μm, inset scale bar = 25 μm), (f) normal AQP4 (AQP4, scale
bar = 250 μm), (g) normal AQP1 (AQP1, scale bar = 250 μm), (h) normal GFAP expression (GFAP, scale bar = 250 μm), and (i) microglial infiltration
(KiM1P, scale bar = 250 μm); (j) Normal appearing gray and (k) white matter show profound microglial activation with rare clusters of small
macrophages (KiM1P, scale bar = 50 μm); Red ischemic neurons (l) and ballooned neurons (m) are present in the normal appearing gray matter
(HE, scale bar = 50 μm).
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cyte’s physiological regulatory volume decrease pre-
serves cell volume homeostasis by releasing inorganic
and organic osmolytes, which in turn are followed by
water [19,20,39,40]. The therapeutic use of a hyperosmolar
solution to rapidly correct chronic hypotonicity causes
endothelial cell shrinkage and blood–brain barrier disrup-
tion, vasogenic edema and increased osmolarity of the
CNS extracellular space [41,42]. Water efflux from astro-
cytes to compensate for intracellular and extracellular os-
molarities, further accentuates the shrinkage of astrocytes.
Loss of AQP4 and AQP1 could represent a protective
mechanism whereby astrocytes restrict water loss and pre-
vent the triggering of apoptosis precipitated by a loss of
cell volume [40,43-49]. The reduced number and smallsize of GFAP-positive (non-apoptotic) astrocytes that we
observed in regions of AQP1 and AQP4 loss within CPM
lesions are compatible with this hypothesis.
In contrast, two of the six CPM cases were character-
ized by astrogliosis associated with increased AQP1 and
AQP4 immunoreactivities. In the setting of vasogenic
edema accompanying CPM, an increase in AQP1 and
AQP4 should facilitate water removal [21,50]. Adminis-
tration of urea or reinduction of hyponatremia during
inadvertent rapid correction of hyponatremia are both
known to decrease the number and severity of CPM le-
sions and to increase AQP4 expression [51-56]. How-
ever, AQPs are only one of several factors that may be
involved in the genesis and resolution of CPM. Although
this was a small series, we did not observe differences
Figure 5 Distribution of AQP1 and AQP4 in the control pons. (a) Myelin immunohistochemistry reveals the characteristic features of the basis
pontis: transverse white matter pontocerebellar tracts (*) and descending white matter corticospinal and coticobulbar tracts (**) intermingled with
pontine grey matter nuclei (x) (PLP, scale bar = 5 mm); (b) Pontine white matter astrocytes preferentially express aquaporin 1 (AQP1) (AQP1, scale
bar = 5 mm); (c) Astrocytes in the pontine nuclei preferentially express aquaporin 4 (AQP4) (AQP4, scale bar = 5 mm); (d) AQP1 in the white
matter is highly concentrated on the membrane of the astrocytic cell bodies (arrow heads) and in all astrocytic foot processes, including those
abutting blood vessels (arrows) (AQP1, scale bar = 100 μm); (e) AQP1 immunoreactivity in the pontine nuclei is preferentially observed around
blood vessels (arrows) and around some, but not all neurons (AQP1, scale bar = 50 μm); (f) AQP4 immunoreactivity in the white matter is mainly
observed around blood vessels (arrows) (AQP4, scale bar = 100 μm); (g) AQP4 positive astrocytic processes in the pontine nuclei envelop the
blood vessels (arrow) as well as all neuronal cell bodies (AQP4, scale bar = 50 μm).
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comes differ in the patients regardless of observed tissue
AQP status.Potential pathogenic consequences of AQPs loss in CPM
AQP4 co-localizes and acts in concert with the inwardly-
rectifying Kir4.1 K+ channel [57-65], the K+ clearing electro
neutral co-transporter NKCC [66], volume regulated anion
channels [67], Ca2+ activated K+ channels [68], the Kv1.5
voltage-gated K+ channel [69], two-pore domain K+ chan-
nel [70,71], transient receptor potential vanniloid related
channel 4 [72] and excitatory amino acid transporter 2
(EAAT2) [73]. Although the co-localization of AQP1 withion channels on CNS astrocytes has not been studied so
far, AQP1 is known to co-localize with the Na-K-2Cl
cotransporter in meningiomas [74], and with the α-
epithelial Na(+) channel in the lung [75]. Therefore, loss of
AQP1 and AQP4 in CPM lesions would be expected to
not only impair bidirectional water fluxes in astrocytes, but
could also impair the transport of ions and organic
osmolytes, and possibly aggravate osmotic stress [76] and
glutamate excitotoxicity [73].Differences in the expression of AQPs in CPM lesions
An unexpected finding in our study was that all CPM
cases exhibiting lesional loss of AQP1 and AQP4





Brief history Probable cause/
underlying cause of
CPM
1 56 M 0 Alcoholism; nausea and vomiting 1 week; hyponatremia, abnormal liver function
tests; presented to Emergency Room in cardiorespiratory arrest.
Rapid correction of
hyponatremia
2 53 M 0 Depression and chronic obstructive pulmonary disease. Not seen for 4 days;




3 33 M 0 Cryptogenic cirrhosis with antitrypsin heterozygosity; orthotopic liver transplant
and hyponatremia followed by progressive obtundation and seizures.
Orthotopic liver
transplant
4 45 M 0 Small-cell lung carcinoma, metastatic to liver; abnormal liver function tests;
possible malnutrition; hyperkalemia; several syncopal episodes in preceding




5 24 F ↑ Hepatic failure and autoimmune thrombocytopenic purpura, 6 months; altered
consciousness level and nonconvulsive status epilepticus 5 weeks before death;
hypocalcemia, hyperammonemia and elevated liver enzymes.
Hepatic failure and
hypocalcemia
6 68 F ↑ Hypertension, obesity, diabetes mellitus, hyperuricemia and remote endometrial
carcinoma (treated by resection, chemotherapy, and radiotherapy); presented
with gangrene of the right fifth toe; generalized seizure followed by
unresponsiveness.
Diabetes mellitus type II
*0 = absent; ↑ = increased.
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cases exhibited a lesional increase in astrocytic AQP im-
munoreactivity. The small number of patients precludes
definitive conclusions concerning sexual dimorphism in
astrocytic AQP regulation. However, female and male sex
hormones have been reported to have opposite effects on
ion transporters, and therefore could exert similar effects
on the expression of water channels. For instance, it
is known that estrogens impair brain adaptation to
hyponatremia whereas androgens enhance it through re-
spective inhibition and stimulation of Na+-K+-ATPase
[77-84]. Furthermore, it is known that estrogen induces
AQP1 expression by activating the estrogen-response
element in the promoter of the Aqp1 gene during angio-
genesis in human breast and endometrial carcinomas [85].
Thus, it is conceivable that in the setting of osmotic stress,
estrogens and androgens could have opposite effects on
AQP1 and AQP4 expression in female and male patients.
If downregulation of AQP1 and AQP4, and/or failure of
their upregulation were an androgen-dependent mechan-
ism, this would, on the one hand protect the astrocyte
from apoptosis, but also be expected to worsen the os-
motic disturbance. This outcome could plausibly explain
the higher incidence of CPM observed in the male popula-
tion [5,16].CPM is also known to occur in association with
a multitude of several underlying conditions, with alcohol-
ism, liver transplantation, malnutrition, hepatic cirrhosis,
burns and SIAD being among the most common. Al-
though most of these conditions cause changes in serum
Na+ levels, changes in other serum osmolytes have also
been associated with CPM including hypokalemia, hyper-
glycemia, hypophosphatemia, and correction of hyper-
ammonemia [11,13-16]. Furthermore, hypoxia and argininevasopressin, in addition to estrogen, affects the brain’s
ability to adapt to cellular edema [39]. Therefore the dif-
ferences observed in the expression of AQP1 and AQP4
among the human CPM lesions may alternatively be
explained by different underlying disease processes that
contributed to the development of CPM.
AQP4 in CPM and NMO
Our findings, corroborated by prior studies, justify con-
sidering CPM a primary astrocytopathy with secondary
demyelination [86-88]. Furthermore, we demonstrate for
the first time that AQP1 and AQP4 contribute to human
CPM pathology and pathogenesis. A primary role for
AQP4 has been associated with neuromyelitis optica
(NMO), an autoimmune inflammatory astrocytopathy
caused by complement-activating IgG autoantibodies di-
rected against AQP4 [88-90]. Early active demyelinating
lesions in both NMO and a subgroup of CPM patients
are characterized by a spectrum of astrocytic damage,
AQP4 loss, retention of small GFAP immunoreactive as-
trocytes with fewer and shorter processes, intramyelinic
edema and apoptosis of oligodendrocytes with secondary
demyelination. Loss of AQP4 in NMO is caused in part
by the internalization of AQP4 by some astrocytes fol-
lowing its interaction with NMO-IgG (antigenic modu-
lation). Complement, when available, is activated by
NMO-IgG remaining on internalization-resistant AQP4
[88-91] expressing astrocytes. In contrast to previously
published studies [92], we did not find evidence for ei-
ther complement activation or AQP4 astrocyte internal-
ization in CPM lesions, suggesting that loss of AQP4
can occur in the absence of complement-activating anti-
bodies. The CPM lesions characterized by AQP4 and
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the absence of antibodies, complement activation or
AQP4 astrocyte internalization, somewhat resemble the
type 6 NMO lesions recently described which show a
more pronounced loss of AQP4 and AQP1 than GFAP,
and also occur in the absence of immunoglobulin depos-
ition or complement activation [27].
We propose that loss of AQP4 and AQP1 in the setting
of CPM may be due to compensatory changes in response
to the local osmotic environment, resulting in astrocytic
injury as a consequence of the osmotic stress. Type 6
NMO lesions may similarly mirror astrocytic injury caused
by osmotic stress due to disturbances of the local osmotic
environment either due to a possible direct effect of
NMO-IgG on water transport [90] or triggered by astro-
cytes in nearby regions that are damaged via antibody-
and complement-mediated mechanisms [88-91].
Conclusions
Our findings provide the first evidence that astrocytic
AQP1 and AQP4 may be involved in the pathogenesis of
CPM. Both are lost in a subset of CPM patients. It re-
mains to be determined whether loss of AQPs in CPM is
a protective compensatory mechanism to protect against
astrocytic apoptosis. Furthermore, additional studies are
needed in order to clarify whether AQP loss is a pa-
thological characteristic of all male patients with CPM,
or rather a feature associated with specific underlying
causes of CPM. Since studies of autopsied human tissues
offer only a single snapshot in disease evolution and
since there are major differences between rodent and
human astrocytes, non-rodent models are needed in
order to better define the complex and dynamic rela-




To characterize AQP1 and AQP4 immunoreactivity and
neuropathological characteristics of CPM, we analyzed
microscopic transverse sections of the pons in archival
autopsied tissue from two control cases (17 year old fe-
male and 15 year old male), and six pathologically con-
firmed CPM cases. Clinical information was obtained
from medical records. The study was approved by the In-
stitutional Review Board of the Mayo Clinic, Rochester.
Neuropathological evaluation and immunohistochemistry
Specimens were fixed in 10–15% formalin and embed-
ded in paraffin. Sections were stained with haematoxy-
lin and eosin (HE) for morphological evaluation and
Luxol-fast blue-periodic acid-Schiff (LFB/PAS) to dem-
onstrate myelin and its degradation products. Lesions
were classified immunohistochemically with respect todemyelinating activity, as previously described [93]. Im-
munohistochemical analyses used avidin–biotin or alkaline
phosphatase/anti-alkaline phosphatase technique without
modification [94]. Tissues were exposed (16 hrs, at 4°C), to
IgGs specific for: AQP1 (rabbit polyclonal 1:500; Santa
Cruz, USA), AQP4 (affinity-purified rabbit polyclonal
1:250; Sigma-Aldrich, USA), myelin proteolipid protein
(PLP, rabbit polyclonal 1:500; Serotec, Oxford, USA), 2′3′-
cyclic-nucleotide 3′-phosphodiesterase (CNPase, mouse
monoclonal 1:2000; Sternberger, USA), myelin oligo-
dendrocyte protein (MOG, mouse monoclonal 1:200; gift
of Dr Sarah Piddlesden, Cardiff, UK), myelin-associated
glycoprotein (MAG, mouse monoclonal 1:10; Chemicon,
USA), glial fibrillary acidic protein (GFAP, mouse monoclo-
nal 1:4000; Dako, Denmark), neurofilament protein (NF,
mouse monoclonal 1:800; Dako, Denmark), T lymphocytes
(CD3, rat monoclonal 1:400; Serotec, USA), macrophages/
microglial cells (KiM1P, mouse monoclonal 1:1000; gift
from Dr. Radzun, University of Göttingen, Germany) and
activated complement antigen (C9neo, mouse monoclonal
1:200; gift from Dr. Paul Morgan, Department of Biochem-
istry, Cardiff, UK). Primary antibodies were omitted in con-
trol staining. Antigen retrieval was performed as previously
described [88].
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